LDS/Medical Tests/Proteomic Blood Test for Non-Small Cell Lung Cancer (NSCLC), VeriStrat

Proteomic Blood Test for Non-Small Cell Lung Cancer (NSCLC), VeriStrat

Lung cancer is a leading cause of death every year. Non-small cell lung cancer (NSCLC) is a subtype of lung cancer that involves the malignant transformation of the epithelial cells in the lungs. The disease has a poor prognosis with 30-50% of NSCLC patients dying within 5 years even after tumor resection. A large proportion of NSCLC tumors have mutations in the EGFR gene that is involved in cellular growth, proliferation, and tumor progression. The gene has a tyrosine kinase domain and interventions with tyrosine kinase inhibitors (TKIs) have been widely adopted in the management of NSCLCs that have common EGFR mutations (exon 19 deletions or exon 21 L858R mutation).

TKIs such as erlotinib, gefitinib, afatinib, osimertinib and dacomitinib have shown clinical efficacy in advanced NSCLC cases harboring common EGFR mutations. However, due to the toxicities associated with TKIs (dermatologic, gastrointestinal, pulmonary) it is desirable to identify advanced NSCLC patients who are likely to benefit from erlotinib and those who are unlikely to have a response in order to avoid the unnecessary toxicities.

Veristrat is test that performs proteomic analysis via the use of matrix-assisted laser desorption ionization mass spectrometry (MALDI TOF MS) of serum samples. The assay analyzes 8 proteins and provides either ‘good’ or ‘poor’ grade to identify patients likely to have progression-free survival (PFS) following erlotinib chemotherapy. While previously the NCCN included Veristrat testing prior to initiating TKI therapy, that recommendation was dropped in the 2021guideline due to advances in both next generation sequencing and treatments.

  • Aids in identifying patients who are likely to benefit from erlotinib chemotherapy
Veristrat Good results: A good result indicates that a patient is more likely to benefit from standard of care (SOC) treatment and have better overall survival (OS). Veristrat Poor results: A poor result indicates that a patient will likely have decreased OS and may benefit from alterative treatment strategies such as novel combination of therapies, NGS testing for rare mutations, non-platinum based regimens, and/or palliative care. Veristrat Indeterminate results: In rare instances (< 2%), a test result of indeterminate is reported, indicating that a Veristrat Good or Veristrat Poor classification could not be confirmed. VeriStrat is not a replacement for an EGFR and other NSCLC associated mutation testing.

No standard reference range is applicable. This is only a categorical test.

Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF MS).

Serum, Serum separator tube (SST).

Stability

  • Ambient: 1-3 days
  • Refrigerated: 3-5 days
EGFR, BRAF gene mutation analysis, sputum cytology, lung biopsy.
3-5 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login